IL33 and neoplasm: In vivo experiments in pancreatic ductal adenocarcinomas (PDACs) have shown that IL-33 induces the activation of tissue-specific immunity, in particular of tissue resident ILC2s and CD8+ T cells, which limits tumor growth.